Millendo Therapeutics begins human trial of VMS drug candidate MLE-301

Millendo Therapeutics has started a phase 1 clinical trial of its selective neurokinin 3 receptor (NK3R) antagonist MLE-301, which is being developed for the treatment ... Read More